Nonalcoholic fatty liver disease: Evolution after gastric bypass;Doença hepática não-alcoólica: Evolução após derivação gastrojejunal em Y-de-Roux pela técnica de Fobi-Capella

Arquivos de Gastroenterologia

Volumn 44, Issue 1, 2007, Pages 49-53

  De Freitas, Alexandre Coutinho Teixeira ^a,b,c   De Freitas, Diane Teixeira ^b   Parolin, Mônica Beatriz ^a   Campos, Antônio Carlos Ligocki ^a,b   Coelho, Júlio Cezar Uili ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^c NONE   (Brazil)

Author keywords

Anastomosis, Roux en Y; Fatty liver; Gastric bypass; Liver diseases; Obesity, morbid

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEPATITIS; HUMAN; HYPERTENSION; INCIDENCE; LIVER BIOPSY; LIVER SURGERY; MALE; MORBIDITY; NONALCOHOLIC FATTY LIVER; STEATOSIS; STOMACH BYPASS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34447511293     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032007000100011     Document Type: Article

References (44)

1. Angulo P, Lindor KD. Treatment of nonalcoholic steatohepatitis. Best practice and research. Clin Gastroenterol. 2002;16:797-810.
2. Astrup A, Ryan L, Grunwald GK, Storgaard M, Saris W, Melanson E. The role of dietary fat in body fatness: evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies. Br J Nutr. 2000;83:s25-s32.
3. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F. Prevalence and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112-7.
4. Berson A, Beco VD, Letteron P, Robin M, Moreau C, Kahwaji JE, Verthier N, Feldmann G, Fromenty B, Pessayre D. Steatohepatits-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114:764-74.
5. Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, Pacini G, Rizzetto M, Pagano G. Postprandial trygliceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. Lipids. 2001;36:1117-24.
6. Chalassani N, Gorski JC, Asghar MS, Ali A, Forseman B, Hall SD. Hepatic cytochrome P450 2E1 activity in non-diabetic patients with non-alcoholic steatohepatitis. Hepatology. 2003;37:544-50.
7. Chitturi S, Abeygunasekera S, Farrel GC, Holmes WJ, Hui JM, Fung C. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-9.
8. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-57.
9. Cotrim HP, Pereira LM, Mattos AA. Doença hepática gordurosa não-alcoólica (DHGNA): inquérito com membros da Sociedade Brasileira de Hepatologia. GED Gastroenterol Endosc Dig. 2004;23;107-12.
10. Day CP, James O. Steatohepatitis: a tale of two hits? Gastroenterology. 1998;114:842-5.
11. Day CP. Nonalcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585-8.
12. De Knegt RJ. Nonalcoholic steatohepatitis: clinical significance and pathogenesis. Scand J Gastroenterol. 2001;234:88-92.
13. Dixon JB, Bhathal OS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-54.
14. Faintuch J, Rudner MA, Machado PLRC, Garrido AB, Oliveira MR, Gama-Rodrigues JJ. Response of comorbidities to Roux-em-Y gastric bypass (RYGBP). Obes Surg. 2001;11:430.
15. Hardman AE. Physical activity, obesity and blood lipids. Int J Obes Relat Metab Disord. 1999;23:s64-s71.
16. Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis. 2004;8:535-7.
17. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenerol Hepatol. 2003;15:539-43.
18. Kern PA, Saghizadeh M, Ong J, Bosh R, Deem R, Simsolo R. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95:2111-9.
19. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-7.
20. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9.
21. Mattos AA. Esteato-hepatite não-alcoólica. J Bras Gastroenterol. 2005;5:160-5.
22. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002;34:255-62.
23. Medina J, Garcia-Buey L, Fernandez-Salazar LI, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27:2057-66.
24. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev. 2002;60:289-93.
25. Moorehead MK, Ardelt-Gattinger E, Lechner H, Oria H. The validation of the Moorehead-Ardelt quality of life questionnaire II. Obes Surg. 2003;13:684-92.
26. Musso G, Gambino R, De Michielli F, Cassader M, Rizzeto M, Durazzo M. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909-16.
27. Neuschwander TBA, Caldwell SH. Nonalcoholis steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-19.
28. Oria HE, Moorehead MK. Bariatric analysis and reporting outcome system (BAROS). Obes Surg. 1999;8:487-99.
29. Punjabi NM, Ahmed MM, Polotsky VY, Beamer BA, O'Donnel CP. Sleep-disordered breathing, glucose intolerance, and insulin resistance. Respir Physiol Neurobiol. 2003;136:167-78.
30. Rashid A, Wu T, Huang C, Chen C, Lin H, Yang S, Lee F, Diehl A. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology. 1999;29:1131-8.
31. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha and steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2001;281:g1333-g9.
32. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-23.
33. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome - the optimal diet. Br J Nutr. 2000;83:s143-s8.
34. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-50.
35. Schafer H, Pauleit D, Sudhop T, Gouni-Berthold I, Ewig S, Berthold HK. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest. 2002;122:829-39.
36. Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515-29.
37. Schoepel KL, Olchowski SE, Mathis MW, Pridgen D, Maxwell JG. Starting a successful bariatric surgical practice in the community hospital setting. Obes Surg. 2001;11:559-64.
38. Sligter K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med. 2004;15:10-21.
39. Stone NJ, Krushner R. Effect of dietary modification and treatment of obesity. Emphasis on improving vascular outcome. Med Clin North Am. 2000;84:95-122.
40. Tilg H, Diehl A. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467-76.
41. Trembley A. Physical activity and obesity Bailliere's best practice and research. Clin Endocrinol Metab. 1999;13:121-9.
42. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochem Biophis Acta. 2002;1585:202-12.
43. Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best practice and research. Clin Gastroenterol. 2002;16:733-47.
44. Zamin I, Mattos AA, Perin C, Ramos GZ. A importância do índice AST/ALT no diagnóstico da esteatohepatite não-alcoólica. Arq Gastroenterol. 2002;39:22-6.